MedPath

FUJIFILM TOYAMA CHEMICAL CO., LTD.

FUJIFILM TOYAMA CHEMICAL CO., LTD. logo
🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

32

Active:12
Completed:16

Trial Phases

3 Phases

Phase 1:11
Phase 2:6
Phase 3:5

Drug Approvals

5

NMPA:5

Drug Approvals

Cefteram Pivoxil Tablets

Product Name
富山龙
Approval Number
国药准字HJ20150489
Approval Date
Nov 16, 2022
NMPA

Cefteram Pivoxil Tablets

Product Name
富山龙
Approval Number
国药准字HJ20150486
Approval Date
Nov 16, 2022
NMPA

Cefteram Pivoxil Tablets

Product Name
富山龙
Approval Number
国药准字HJ20150490
Approval Date
Nov 16, 2022
NMPA

Cefteram Pivoxil Tablets

Product Name
富山龙
Approval Number
国药准字HJ20150487
Approval Date
Nov 16, 2022
NMPA

Garenoxacin Mesilate Tablets

Product Name
甲磺酸加诺沙星片
Approval Number
H20190043
Approval Date
Jul 12, 2019
NMPA

Clinical Trials

Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials

Phase 1
11 (50.0%)
Phase 2
6 (27.3%)
Phase 3
5 (22.7%)

Efficacy and Safety of FF-31501 in Meniscus Tear Patients

Phase 3
Active, not recruiting
Conditions
Meniscus Injury
First Posted Date
2023-03-21
Last Posted Date
2024-02-02
Lead Sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Target Recruit Count
18
Registration Number
NCT05777967
Locations
🇯🇵

Medical corporation keimeikai Juko Osu hospital, Aichi, Japan

🇯🇵

Wakamatsu Hospital of the University of OccupationalOC and Environmental Health, Fukuoka, Japan

🇯🇵

Mie Prefectural General Medical Center, Mie, Japan

and more 1 locations

Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Phase 2
Completed
Conditions
Mild Cognitive Impairment
Interventions
Drug: Placebo
First Posted Date
2019-12-09
Last Posted Date
2023-10-23
Lead Sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Target Recruit Count
221
Registration Number
NCT04191486
Locations
🇨🇿

FNUSA - Mezinarodni centrum klinickeho vyzkumu, Brno, Czechia

🇨🇿

FNHK - Neurologicka klinika, Hradec Králové, Czechia

🇨🇿

A-shine, s.r.o., Plzen, Czechia

and more 34 locations

PK Study of T-817 in Subjects With Hepatic Impairment

Phase 1
Completed
Conditions
Healthy
Hepatic Impairment
Interventions
First Posted Date
2016-02-26
Last Posted Date
2017-11-24
Lead Sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Target Recruit Count
36
Registration Number
NCT02693197
Locations
🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: T-817MA-L
Drug: Placebo
Drug: T-817MA-H
First Posted Date
2014-03-06
Last Posted Date
2019-02-26
Lead Sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Target Recruit Count
482
Registration Number
NCT02079909
Locations
🇺🇸

Banner Alzheimer's Institute, Phoenix, Arizona, United States

🇺🇸

Banner Sun Health Research Institute, Sun City, Arizona, United States

🇺🇸

University of Arizona Health Sciences Center, Tucson, Arizona, United States

and more 47 locations

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
First Posted Date
2008-04-22
Last Posted Date
2013-11-05
Lead Sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Target Recruit Count
373
Registration Number
NCT00663936
Locations
🇺🇸

Banner Alzheimer's Institute, Phoenix, Arizona, United States

🇺🇸

Northwest NeuroSpecialists, Tucson, Arizona, United States

🇺🇸

Collaborative Neuroscience Network, Inc., Garden Grove, California, United States

and more 32 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.